adesso 미래 성장

XTRA:ADN1 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	1,639	39	61	95	6
12/31/2025	1,468	27	43	79	6
12/31/2024	1,304	12	16	55	6
9/30/2024	1,269	5	102	135	N/A
6/30/2024	1,225	-1	94	129	N/A
3/31/2024	1,182	-2	51	83	N/A
12/31/2023	1,140	3	43	77	N/A
9/30/2023	1,084	5	-23	7	N/A
6/30/2023	1,037	12	-28	-1	N/A
3/31/2023	969	18	7	35	N/A
12/31/2022	901	29	12	36	N/A
9/30/2022	836	29	12	36	N/A
6/30/2022	769	28	12	33	N/A
3/31/2022	725	37	17	36	N/A
12/31/2021	678	48	30	48	N/A
9/30/2021	636	45	23	43	N/A
6/30/2021	600	46	23	37	N/A
3/31/2021	564	42	34	47	N/A
12/31/2020	524	21	54	65	N/A
9/30/2020	503	24	34	40	N/A
6/30/2020	484	19	34	43	N/A
3/31/2020	467	18	22	33	N/A
12/31/2019	451	17	11	22	N/A
9/30/2019	432	15	1	13	N/A
6/30/2019	412	13	-9	3	N/A
3/31/2019	395	13	0	10	N/A
12/31/2018	378	14	9	18	N/A
9/30/2018	364	14	14	22	N/A
6/30/2018	351	14	N/A	26	N/A
3/31/2018	336	13	N/A	23	N/A
12/31/2017	322	11	N/A	20	N/A
9/30/2017	307	11	N/A	17	N/A
6/30/2017	292	11	N/A	13	N/A
3/31/2017	276	12	N/A	14	N/A
12/31/2016	261	12	N/A	15	N/A
9/30/2016	245	10	N/A	14	N/A
6/30/2016	229	7	N/A	14	N/A
3/31/2016	213	6	N/A	15	N/A
12/31/2015	197	5	N/A	17	N/A
9/30/2015	183	4	N/A	17	N/A
6/30/2015	169	4	N/A	16	N/A
3/31/2015	163	4	N/A	13	N/A
12/31/2014	157	3	N/A	9	N/A
9/30/2014	151	3	N/A	7	N/A
6/30/2014	145	2	N/A	5	N/A
3/31/2014	140	3	N/A	7	N/A
12/31/2013	135	3	N/A	8	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ADN1 의 연간 예상 수익 증가율( 42.3% )이 saving rate( 1% 보다 높습니다. ).

수익 vs 시장: ADN1 의 연간 수익( 42.3% ) German 시장( 21.1% 보다 빠르게 성장할 것으로 예상됩니다. 21.1% 연간).

고성장 수익: ADN1 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: ADN1 의 수익(연간 11.5% ) German 시장( 5.6% 보다 빠르게 성장할 것으로 예상됩니다. 5.6% 연간).

고성장 수익: ADN1 의 수익(연간 11.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ADN1 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 12.9 %).

adesso 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

adesso SE (ETR:ADN1) Just Reported, And Analysts Assigned A €122 Price Target

Price target decreased by 7.4% to €162

Consensus EPS estimates fall by 13%

Analysts Are Updating Their adesso SE (ETR:ADN1) Estimates After Its Annual Results

Consensus EPS estimates fall by 63%, revenue upgraded

Consensus EPS estimates fall by 61%

Recent updates

adesso (ETR:ADN1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

adesso SE (ETR:ADN1) Just Reported, And Analysts Assigned A €122 Price Target

Third quarter 2024 earnings released: EPS: €1.67 (vs €0.85 in 3Q 2023)

Does adesso (ETR:ADN1) Have A Healthy Balance Sheet?

Now 24% overvalued

It's Down 25% But adesso SE (ETR:ADN1) Could Be Riskier Than It Looks

Second quarter 2024 earnings released: €1.02 loss per share (vs €1.18 loss in 2Q 2023)

Price target decreased by 7.4% to €162

Upcoming dividend of €0.70 per share

New major risk - Financial position

adesso's (ETR:ADN1) Shareholders Will Receive A Bigger Dividend Than Last Year

New major risk - Financial position

adesso (ETR:ADN1) Has Announced That It Will Be Increasing Its Dividend To €0.70

Returns On Capital Signal Tricky Times Ahead For adesso (ETR:ADN1)

Investors Can Find Comfort In adesso's (ETR:ADN1) Earnings Quality

Consensus EPS estimates fall by 13%

Analysts Are Updating Their adesso SE (ETR:ADN1) Estimates After Its Annual Results

Full year 2023 earnings: EPS misses analyst expectations

Is adesso SE (ETR:ADN1) Trading At A 44% Discount?

adesso SE (ETR:ADN1) Soars 29% But It's A Story Of Risk Vs Reward

Consensus EPS estimates fall by 63%, revenue upgraded

Dividend increased to €0.70

A Look At The Intrinsic Value Of adesso SE (ETR:ADN1)

Consensus EPS estimates fall by 61%

adesso SE to Report Fiscal Year 2023 Results on Mar 25, 2024

adesso SE to Report Q3, 2024 Results on Nov 14, 2024

Third quarter 2023 earnings released: EPS: €0.85 (vs €2.01 in 3Q 2022)

New minor risk - Earnings quality

Consensus EPS estimates fall by 19%

Does adesso (ETR:ADN1) Have A Healthy Balance Sheet?

adesso SE Announces CEO Changes

Consensus EPS estimates fall by 14%, revenue upgraded

Second quarter 2023 earnings released: €1.18 loss per share (vs €0.29 loss in 2Q 2022)

Now 22% undervalued after recent price drop

At €106, Is It Time To Put adesso SE (ETR:ADN1) On Your Watch List?

Now 20% undervalued after recent price drop

adesso SE Announces Board Changes

Calculating The Intrinsic Value Of adesso SE (ETR:ADN1)

Now 21% undervalued after recent price drop

Upcoming dividend of €0.65 per share at 0.5% yield

First quarter 2023 earnings released: EPS: €0.28 (vs €1.92 in 1Q 2022)

Consensus EPS estimates fall by 10%, revenue upgraded

adesso's (ETR:ADN1) Returns On Capital Not Reflecting Well On The Business

Now 24% undervalued after recent price drop

What Does adesso SE's (ETR:ADN1) Share Price Indicate?

Now 21% undervalued after recent price drop

adesso SE (XTRA:ADN1) signed an agreement to acquire 51% stake in Wepex GmbH.

adesso (ETR:ADN1) Has A Pretty Healthy Balance Sheet

Returns On Capital At adesso (ETR:ADN1) Have Stalled

adesso SE (XTRA:ADN1) acquired WebScience Srl.

Calculating The Fair Value Of adesso SE (ETR:ADN1)

At €138, Is It Time To Put adesso SE (ETR:ADN1) On Your Watch List?

adesso SE to Report Q1, 2023 Results on May 15, 2023

Third quarter 2022 earnings released: EPS: €2.01 (vs €1.86 in 3Q 2021)

We Think adesso (ETR:ADN1) Can Stay On Top Of Its Debt

Price target decreased to €208

Second quarter 2022 earnings released: €0.29 loss per share (vs €1.12 profit in 2Q 2021)

adesso SE Revises Earnings Guidance for the Full Year 2022

Why adesso SE (ETR:ADN1) Could Be Worth Watching

adesso SE Revises Earnings Guidance for the Full Year 2022

adesso SE (XTRA:ADN1) acquired Quadox Ag.

adesso (ETR:ADN1) Hasn't Managed To Accelerate Its Returns

adesso SE (XTRA:ADN1) acquired remaining 41% stake in com2m GmbH.

Investor sentiment deteriorated over the past week

Now 22% undervalued after recent price drop

Upcoming dividend of €0.60 per share

First quarter 2022 earnings: EPS exceeds analyst expectations

Is adesso (ETR:ADN1) A Risky Investment?

Now 22% undervalued after recent price drop